128
Participants
Start Date
November 30, 2010
Primary Completion Date
November 30, 2014
Study Completion Date
November 30, 2014
Nilotinib
Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
Montefiore Medical Center, The Bronx
University of Rochester Medical Ct James P Wilmot Cancer Ctr, Rochester
University of Maryland, Baltimore
University of Virginia, Charlottesville
Duke University Medical Center Duke University Med Ctr, Durham
Cancer Centers of the Carolinas Cancer Center, Greenville
Georgia Regents University MedCollege of GA Cancer Ctr 2, Augusta
Sarah Cannon Research Institute SCRI, Jacksonville
Advanced Medical Specialties, Miami
Pasco Hernando Oncology, New Port Richey
Tennessee Oncology Sarah Cannon Research Inst., Nashville
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology, Chattanooga
The Jones Clinic, Germantown
Indiana Blood and Marrow Institute, Beach Grove
Henry Ford Hospital, Detroit
Stroger Cook County Hospital Division of Hematology & Onc, Chicago
Louis A. Weiss Memorial Hospital, Chicago
St. Louis University Cancer Center, St Louis
University of Nebraska Medical Center University of Nebraska Med Ctr, Omaha
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center(3), New Orleans
Baylor Research Institute Baylor Research Institute (17), Dallas
Oncology Consultants Oncology Consultants, P.A., Houston
Millennium Oncology, Houston
Pacific Cancer Medical Center, Inc., Anaheim
St. Jude Heritage Medical Group Virginia Crosson Cancer Center, Yorba Linda
Bay Area Cancer Research Dept.ofBayAreaCancerResearch, Concord
Oregon Health & Science University, Portland
Providence Regional Cancer Partnership, Everett
Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer, Burbank
Cancer Center of Kansas, Witchita
Dana Farber Cancer Institute, Boston
Hackensack University Medical Center Dept.of HackensackUniv.MedCtr., Hackensack
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY